FLT4 and gastroesophageal junction adenocarcinoma: Since cisplatin relies on ERK activation for bioactivity in some cells [41,44], in contrast to oxaliplatin [50], this might explain the chemosensitivity of VEGFR-3 and CXCR4 positive esophagogastric adenocarcinoma to FLP and not to FLO.